Your browser is no longer supported. Please, upgrade your browser.
AGIO [NASD]
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.46 Insider Own0.30% Shs Outstand69.54M Perf Week1.00%
Market Cap3.85B Forward P/E- EPS next Y-6.36 Insider Trans-2.27% Shs Float61.51M Perf Month5.65%
Income-378.00M PEG- EPS next Q-1.41 Inst Own95.10% Short Float8.99% Perf Quarter-0.13%
Sales116.10M P/S33.17 EPS this Y30.80% Inst Trans0.66% Short Ratio7.48 Perf Half Y32.49%
Book/sh33.02 P/B1.69 EPS next Y-124.90% ROA121.50% Target Price64.88 Perf Year40.75%
Cash/sh33.81 P/C1.65 EPS next 5Y40.00% ROE170.00% 52W Range32.47 - 58.93 Perf YTD28.66%
Dividend- P/FCF- EPS past 5Y-8.60% ROI- 52W High-5.40% Beta1.66
Dividend %- Quick Ratio- Sales past 5Y28.00% Gross Margin98.00% 52W Low71.70% ATR2.09
Employees562 Current Ratio24.40 Sales Q/Q- Oper. Margin- RSI (14)57.56 Volatility4.11% 3.80%
OptionableYes Debt/Eq0.00 EPS Q/Q-6.60% Profit Margin- Rel Volume1.02 Prev Close55.79
ShortableYes LT Debt/Eq0.00 EarningsApr 29 BMO Payout0.00% Avg Volume739.46K Price55.75
Recom2.10 SMA201.92% SMA507.25% SMA20024.34% Volume769,654 Change-0.07%
Mar-01-21Upgrade SVB Leerink Mkt Perform → Outperform $50
Mar-01-21Downgrade JP Morgan Overweight → Neutral $64 → $54
Feb-26-21Downgrade SVB Leerink Outperform → Mkt Perform
Oct-22-20Upgrade Barclays Equal Weight → Overweight $46
Mar-04-20Initiated Barclays Equal Weight $50
Nov-26-19Initiated Cantor Fitzgerald Overweight $64
Sep-23-19Upgrade Guggenheim Neutral → Buy $55
May-23-19Resumed Goldman Neutral $55
Feb-15-19Upgrade SVB Leerink Mkt Perform → Outperform $80
Sep-25-18Initiated Leerink Partners Mkt Perform
May-23-18Initiated Citigroup Buy $117
Apr-11-18Reiterated Credit Suisse Outperform $80 → $95
Feb-15-18Reiterated SunTrust Buy $80 → $101
Feb-15-18Reiterated Needham Buy $72 → $86
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Aug-02-17Upgrade Leerink Partners Mkt Perform → Outperform $80
Jun-26-17Downgrade Janney Buy → Neutral
Jan-17-17Upgrade Oppenheimer Perform → Outperform
May-02-21 03:08AM  
Apr-30-21 08:46AM  
Apr-29-21 06:30PM  
09:25AM  
07:00AM  
05:45AM  
Apr-22-21 12:33PM  
Apr-20-21 11:56AM  
Apr-15-21 07:00AM  
Apr-01-21 07:00AM  
Mar-27-21 11:31AM  
Mar-25-21 04:01PM  
Mar-18-21 07:00AM  
Mar-01-21 07:00AM  
Feb-27-21 01:04AM  
Feb-26-21 10:04AM  
09:21AM  
07:00AM  
Feb-25-21 07:00PM  
07:00AM  
06:15AM  
Feb-23-21 07:00AM  
Feb-11-21 07:00AM  
Feb-04-21 11:54PM  
Jan-27-21 07:35AM  
Jan-26-21 04:01PM  
Jan-17-21 10:00AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Dec-23-20 08:30AM  
Dec-22-20 10:22AM  
07:39AM  
Dec-21-20 04:25PM  
01:46PM  
11:44AM  
10:10AM  
09:30AM  
07:39AM  
07:00AM  
07:00AM  
Dec-20-20 05:16PM  
Dec-07-20 04:30PM  
Dec-05-20 11:31AM  
Dec-04-20 08:00AM  
Dec-02-20 10:55AM  
Dec-01-20 07:00AM  
Nov-30-20 07:00AM  
Nov-25-20 07:00AM  
Nov-20-20 10:14AM  
Nov-13-20 10:57AM  
Nov-12-20 04:30PM  
Nov-07-20 07:16AM  
Nov-06-20 11:20AM  
Nov-05-20 09:00PM  
08:23AM  
07:00AM  
06:15AM  
Nov-04-20 11:46AM  
Oct-30-20 06:29AM  
Oct-29-20 04:01PM  
12:35PM  
Oct-22-20 12:34PM  
07:00AM  
Oct-19-20 12:06PM  
Oct-16-20 04:01PM  
Oct-05-20 12:00PM  
Sep-21-20 07:00AM  
Sep-16-20 05:10PM  
Sep-08-20 04:01PM  
Sep-05-20 07:27AM  
Aug-31-20 06:35AM  
Aug-29-20 11:31AM  
Aug-27-20 07:00AM  
Aug-06-20 07:00AM  
Jul-30-20 10:01PM  
09:55AM  
07:00AM  
Jul-23-20 12:32PM  
Jul-17-20 12:46PM  
Jul-16-20 07:01AM  
Jul-10-20 07:16AM  
Jul-02-20 06:08AM  
Jun-19-20 01:21AM  
Jun-18-20 12:00PM  
Jun-17-20 04:01PM  
10:56AM  
Jun-12-20 04:23PM  
03:41PM  
06:30AM  
02:30AM  
02:30AM  
Jun-10-20 11:30AM  
Jun-09-20 11:29AM  
Jun-08-20 04:01PM  
01:25PM  
May-30-20 11:31AM  
May-29-20 08:00AM  
May-28-20 11:56AM  
May-21-20 11:30AM  
May-19-20 07:00AM  
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alenson CarmanPrincipal Accounting OfficerApr 16Sale55.891,11862,4850Apr 20 04:10 PM
Alenson CarmanPrincipal Accounting OfficerApr 15Sale54.0099153,5141,118Apr 16 04:33 PM
Miles DarrinChief Commercial OfficerMar 05Sale48.5850024,29010,671Mar 16 04:14 PM
Miles DarrinChief Commercial OfficerMar 01Sale47.992,200105,57811,171Mar 16 04:14 PM
Miles DarrinChief Commercial OfficerFeb 22Option Exercise0.00725013,272Feb 24 04:14 PM
Schenkein David PDirectorFeb 22Option Exercise0.002,7740113,412Feb 24 04:12 PM
Bowden ChristopherChief Medical OfficerFeb 22Option Exercise0.003,334016,396Feb 24 04:11 PM
Alenson CarmanPrincipal Accounting OfficerFeb 22Option Exercise0.0069201,994Feb 24 04:12 PM
Bowden ChristopherChief Medical OfficerFeb 16Option Exercise0.002,750015,131Feb 17 04:14 PM
Miles DarrinChief Commercial OfficerFeb 16Option Exercise0.00922015,463Feb 17 04:14 PM
Schenkein David PDirectorFeb 16Option Exercise0.008,1250113,178Feb 17 04:12 PM
Alenson CarmanPrincipal Accounting OfficerFeb 16Option Exercise0.0079001,863Feb 17 04:13 PM
Bowden ChristopherChief Medical OfficerFeb 14Option Exercise0.004,000012,381Feb 17 04:14 PM
Miles DarrinChief Commercial OfficerFeb 14Option Exercise0.008,666014,541Feb 17 04:14 PM
Alenson CarmanPrincipal Accounting OfficerFeb 14Option Exercise0.0088901,073Feb 17 04:13 PM
FOUSE JACQUALYN AChief Executive OfficerFeb 14Option Exercise0.0011,333061,761Feb 17 04:13 PM
Car BruceChief Scientific OfficerJan 06Option Exercise0.003,43708,284Apr 15 04:46 PM
Biller JonathanChief Financial OfficerDec 03Option Exercise0.005,753011,747Dec 07 06:21 PM
Alenson CarmanPrincipal Accounting OfficerSep 02Sale39.932509,982184Sep 04 04:24 PM
Bowden ChristopherChief Medical OfficerMay 20Option Exercise35.163,583125,97811,889May 21 05:05 PM
Bowden ChristopherChief Medical OfficerMay 20Sale50.013,583179,2008,306May 21 05:05 PM